Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer

I-SPY2 is an adaptively randomized phase 2 clinical trial evaluating novel agents in combination with standard-of-care paclitaxel followed by doxorubicin and cyclophosphamide in the neoadjuvant treatment of breast cancer. Ganitumab is a monoclonal antibody designed to bind and inhibit function of th...

Descripción completa

Detalles Bibliográficos
Autores principales: Yee, Douglas, Isaacs, Claudine, Wolf, Denise M., Yau, Christina, Haluska, Paul, Giridhar, Karthik V., Forero-Torres, Andres, Jo Chien, A., Wallace, Anne M., Pusztai, Lajos, Albain, Kathy S., Ellis, Erin D., Beckwith, Heather, Haley, Barbara B., Elias, Anthony D., Boughey, Judy C., Kemmer, Kathleen, Yung, Rachel L., Pohlmann, Paula R., Tripathy, Debu, Clark, Amy S., Han, Hyo S., Nanda, Rita, Khan, Qamar J., Edmiston, Kristen K., Petricoin, Emanuel F., Stringer-Reasor, Erica, Falkson, Carla I., Majure, Melanie, Mukhtar, Rita A., Helsten, Teresa L., Moulder, Stacy L., Robinson, Patricia A., Wulfkuhle, Julia D., Brown-Swigart, Lamorna, Buxton, Meredith, Clennell, Julia L., Paoloni, Melissa, Sanil, Ashish, Berry, Scott, Asare, Smita M., Wilson, Amy, Hirst, Gillian L., Singhrao, Ruby, Asare, Adam L., Matthews, Jeffrey B., Hylton, Nola M., DeMichele, Angela, Melisko, Michelle, Perlmutter, Jane, Rugo, Hope S., Fraser Symmans, W., van‘t Veer, Laura J., Berry, Donald A., Esserman, Laura J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8492731/
https://www.ncbi.nlm.nih.gov/pubmed/34611148
http://dx.doi.org/10.1038/s41523-021-00337-2

Ejemplares similares

Ejemplares similares